Work

Optimizing the Dosing of Post-Transplantation Cyclophosphamide in a Murine Haploidentical Allogeneic Hematopoietic Cell Transplantation Model

Year: 2017

Type: article

Abstract: Initial pre-clinical studies of post-transplantation cyclophosphamide (PTCy) in allogeneic hematopoietic cell transplantation (alloHCT) adopted the dosing of 200 mg/kg on day +2 or +3 shown to be effective in murine skin allografting models. When translated clinically, PTCy initially was given as a single high dose (50 mg/kg) on day +3. A follow-up study suggested that adding a second dose on day +4 might be associated with a decreased risk of extensive chronic GVHD. Subsequently, almost all clinical studies have used PTCy at 50 mg/kg as two doses on either days +3/4 or +3/5.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2016.12.333

Authors: Lucas P. Wachsmuth, Ehydel Castro, Ronald E. Gress, Christopher G. Kanakry

Institutions: National Institutes of Health, National Cancer Institute

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650